Skip to content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Principal Investigator


Dr. Pike received his B.Sc. (Hons) degree in chemistry from the University of Birmingham (UK) in 1972 and his Ph.D. in organic chemistry from the same University in 1975. Following a postdoctoral fellowship at Birmingham University, he joined the MRC Cyclotron Unit (Imperial College, London) in 1978 at the foundation of its strong research program in positron emission tomography (PET), eventually becoming Head of its Chemistry and Engineering Section with a strong personal interest in all chemical aspects of the discovery, development and evaluation of novel radioactive probes for molecular imaging with PET. Dr. Pike was awarded the Marie Curie Award and Springer Prize for his work in this area. He joined the Molecular Imaging Branch of NIMH in 2001 as Chief of the PET Radiopharmaceutical Sciences Section (PRSS).

Research Interests

Dr. Pike’s Section is focused on developing novel radioactive probes (radiotracers) for the investigation of neuropsychiatric disorders with PET. This research mainly encompasses medicinal chemistry for probe discovery and radiochemistry for labeling candidate probes with a short–lived positron-emitter, invariably cyclotron-produced carbon-11 (t1/2 = 20 min) or fluorine-18 (t1/2 = 110 min).

PET is a uniquely powerful means for investigating the biochemical workings of the brain in living human subjects, including those suffering from neuropsychiatric disorders.  The power of PET in clinical research derives from the use of radiotracers that are specific for a particular important biochemical process (e.g., glucose metabolism) or a low-density protein target (e.g., a neurotransmitter receptor), where the process or target is suspected of playing a major role in one or more brain disorders (e.g. the serotonin transporter in depression).   Currently, radiotracers do not exist for the myriad of possible targets.  The discovery and development of suitable radiotracers is in fact a major challenge in realizing the full research potential of PET (much like drug discovery).  

In Dr. Pike’s laboratory, radiotracers for imaging and quantifying various protein targets (e.g., plaques, transporters, or neurotransmitter receptors) in brain are in development.  These targets include Aβ-amyloid plaque, TSPO (previously known as PBR) binding sites, the efflux transporter P-gp and the receptors mGluR5, CB1 and 5-HT1A.  Candidate probes are evaluated in animal and normal human subjects in close cooperation with the Imaging Section of the Molecular Imaging Branch, led by Dr. Innis.  Successful probes are then introduced into clinical studies with PET for investigating various disorders, such as neuroinflammatory conditions (stroke, Alzheimer’s disease, and traumatic brain injury), addiction (alcoholism), autism, anxiety and depression.

Development of methodology for radiolabeling with carbon-11 and fluorine-18 is key to successful radiotracer development, and is a major component of the Section's research.  Currently, this includes the exploration of i) methods to accelerate labeling reactions (e.g., the use of microfluidics or microwaves), ii) chemistry to allow fluorine-18 to be introduced into previously inaccessible molecular positions, iii) semi-robotic approaches to safe and reliable radiotracer production, and iv) the use of mass spectrometry to independently verify radiotracer specific activity, investigate metabolic pathways and provide arterial input functions for PET imaging.

A full list of publications and more information on the research activities of Dr. Pike’s laboratory are available at the laboratory Web Site.

Selected Publications

Singh P, Shrestha S, Cortes-Salva MY, Jenko KJ, Zoghbi SS, Morse CL, Innis RB, Pike VW (2018). 3-Substituted 1,5-Diaryl-1 H-1,2,4-triazoles as Prospective PET Radioligands for Imaging Brain COX-1 in Monkey. Part 1: Synthesis and Pharmacology. ACS Chem Neurosci 9, 2610-2619. [Pubmed Link]

Zanotti-Fregonara P, Xu R, Zoghbi SS, Liow JS, Fujita M, Veronese M, Gladding RL, Rallis-Frutos D, Hong J, Pike VW, Innis RB (2016). The PET Radioligand 18F-FIMX Images and Quantifies Metabotropic Glutamate Receptor 1 in Proportion to the Regional Density of Its Gene Transcript in Human Brain. J Nucl Med 57, 242-7. [Pubmed Link]

Shrestha S, Singh P, Cortes-Salva MY, Jenko KJ, Ikawa M, Kim MJ, Kobayashi M, Morse CL, Gladding RL, Liow JS, Zoghbi SS, Fujita M, Innis RB, Pike VW (2018). 3-Substituted 1,5-Diaryl-1 H-1,2,4-triazoles as Prospective PET Radioligands for Imaging Brain COX-1 in Monkey. Part 2: Selection and Evaluation of [11C]PS13 for Quantitative Imaging. ACS Chem Neurosci 9, 2620-2627. [Pubmed Link]

Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, Taliani S, Da Settimo F, Fujita M, Pike VW, Innis RB, Biomarkers Consortium Radioligand Project Team (2017). 11C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. J Nucl Med 58, 320-325. [Pubmed Link]

Haskali MB, Pike VW (2017). [11 C]Fluoroform, a Breakthrough for Versatile Labeling of PET Radiotracer Trifluoromethyl Groups in High Molar Activity. Chemistry 23, 8156-8160. [Pubmed Link]

Magnuson Clinical Center, Room B3C346, MSC 1003

Phone: +1 301 594 5986
Fax: +1 301 480 5112